Genmab — Maj 2020
-
Og senere: "And we will not actually let the coronavirus troubles hinder that because we actually think that we can turn this era into an advantage potentially for Genmab and for the partner for epcoritamab because we know that some of the large Phase III trials from competing programs like the Roche CD20 -- CD3/CD20 bispecific programs are on hold right now, whereas we are still recruiting patients and planning new studies."
-
Tør jeg mon gentage spørgsmålet fra i nat: "Hvorfor understreger Jan igen og igen, at de vil have US commercial rights/co-promotion - det er vel lige meget hvem af partnerne der sælger hvor og hvor meget... når man alligevel, ved dagens slutning, deler pengene?!
-
ja men Genmab kan rekruttere, fordi det er patienternes sidste udvej!
-
så burde Roche jo også kunne rekruttere nye patienter
-
så et bevis på at Genmab er "best in class" og hvis Roche er på hold i længere tid, så vil Genmab også være "first in class"
-
det kommer jo anpå hvor lang tid Roche er på hold
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind